Biopharma’s boom-era org charts are giving way to leaner, faster operating models. Slone Partners CEO, Leslie Loveless, says the edge now goes to pragmatic builders: “The companies that win right now are hiring leaders who can do more with less.”
Published 4 Mar 2026
After years studying Stargardt’s natural history, Belite Bio’s Dr. Hendrik Scholl is championing Tinlarebant as a practical early intervention - “Intervention is simply one pill a day - and we are able to slow down the progression of disease by more than one-third.”
Published 20 Feb 2026
Belite is positioning Tinlarebant for regulatory submission after Phase 3 Stargardt data, emphasizing the long-term safety burden of a systemic, lifelong oral therapy: “For a lifelong treatment, the safety bar is about as high as it gets.”
Published 18 Feb 2026
Copper replacement formalizes care for a fatal pediatric metabolic disorder.
Published 2 Feb 2026
The sublingual epinephrine film's path to market is delayed by human factors issues, though no safety or efficacy concerns were raised in the Complete Response Letter
Published 30 Jan 2026
Outpace Bio is using AI-powered protein design to build “software and hardware” into engineered cells aimed at durable solid-tumor responses. For CEO Marc Lajoie, “efficacy is still the fundamental problem that needs to be solved - efficacy and safety.”
Published 30 Jan 2026
“Everything that’s good for patients delivers extraordinary value for biopharma - that overlap is the entire company,” says Shashi Shankar, CEO. From symptom tracking to AI-driven normalization, Novellia builds patient-first data infrastructure that scales into biopharma-grade intelligence.
Published 28 Jan 2026
As pharma’s demand for real-time lab intelligence accelerates, Prognos Health is leaning in - and after six or seven years of building, the company now sees “a real path to delivering 20 billion health insights by 2050”, says CEO Sundeep Bhan.
Published 26 Jan 2026
Vivodyne’s automated human-testing platform aims to deliver unprecedented scale, reproducibility, and biological fidelity in preclinical drug testing - powered by patient-derived tissues that “already know the instructions,” as CEO Andrei Georgescu puts it.
Published 23 Jan 2026
With Bridgewater online and global facilities underway, Cellares is moving from platform development to commercial execution. CEO Fabian Gerlinghaus says, “Our factories can produce as many therapies as ten manual facilities - with just ten percent of the people.”
Published 22 Jan 2026
Paula Brown Stafford argues that real differentiation now comes from pairing global operations with smart, disciplined innovation. “We're adding AI as a teammate, but we still need our team to have their own expertise to ask the right questions.”
Published 21 Jan 2026
At 4G Clinical, David Kelleher articulates a leadership philosophy built on precision, flexibility, and the belief that execution failures in trials carry real human consequences: “We will never mis-randomize, stock out, miss dose, or compromise the blind.”
Published 20 Jan 2026
DNAnexus is pushing precision medicine out of research silos to improve care delivery. As CEO Thomas Laur puts it, “The future isn’t moving data into one big bucket. It’s moving algorithms to federated data,” enabling distributed clinical decisions at scale.
Published 19 Jan 2026
As traditional drug discovery reaches its limits, Xaira is pushing toward a more predictive, AI-native model. CEO Marc Tessier-Lavigne says, “we’re turning this broken, artisanal endeavor into something much closer to an engineering discipline.”
Published 16 Jan 2026
“If we don’t detect cancer early and intervene, it’s very hard to talk about a cure.” Freenome is betting that data scale, commercial discipline, and blood-based screening can finally close oncology’s early-detection gap.
Published 15 Jan 2026
The machinery that governs gene expression is being targeted to beat cancer.
Published 14 Jan 2026
London · 15–19 November 2026
Explore Onyx’s independent guide to the events and make the most of your week in London.
